Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eliem Therapeutics (ELYM) has shared an announcement.
Eliem Therapeutics, Inc. has appointed Brett Kaplan, M.D., as its Chief Operating Officer, effective August 26, 2024. Dr. Kaplan, with a solid background in finance and biotechnology, previously held leadership roles at Chroma Medicine, Prevail Therapeutics, and Evercore Partners. Under the terms of his employment, he will receive a $500,000 base salary, up to a 45% annual bonus, and equity in the form of stock options and restricted stock units. His compensation package also includes standard employee benefits and specific severance terms if employment ends under certain conditions.
Learn more about ELYM stock on TipRanks’ Stock Analysis page.